Pharmaceuticals
Ceasing their 2016 distribution deal Sun Pharma and AstraZeneca Pharma enter into a transition supply agreement
Mumbai/UNI: AstraZeneca India and Sun Pharma have now discontinued their distribution agreement signed in 2016 and have entered into a transition supply agreement with effect from today.
Sun Pharma had earlier announced its distribution services agreement between the pharma major and AstraZeneca Pharma Ltd. India for the distribution of Dapagliflozin, an innovative Type 2 diabetes medicine, in India.
Under the current agreement, AstraZeneca India has granted rights to Sun Pharma to promote and distribute Dapagliflozin under the brand name "Oxra".
Sun Pharma has now gained the rights to promote and distribute the combination of Dapagliflozin with Metformin under the brand name "Oxramet" and the combination of Dapagliflozin and Saxagliptin under the brand name "Oxraduo".
In addition, Sun Pharma has also taken a patent license to manufacture and commercialize Dapagliflozin and Dapagliflozin with Metformin combination in India from AstraZeneca AB.
Under the transition supply agreement, AstraZeneca India will supply Dapagliflozin and the same with Metformin to Sun Pharma till mutually agreed between the parties, post which all supplies to Sun Pharma from AstraZeneca India shall cease.
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
